醫療事務的評價(美國)- 慢性骨髓性白血病
市場調查報告書
商品編碼
1803884

醫療事務的評價(美國)- 慢性骨髓性白血病

Medical Affairs Reputations (US) - Chronic Myeloid Leukemia

出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告是根據血液科醫師和腫瘤科醫師的定量調查,檢視了美國支持慢性骨髓性白血病 (CML) 治療的醫療事務團隊的績效和聲譽。報告提供了醫生互動頻率、首選溝通管道、對當前支援的滿意度以及關鍵未滿足需求的數據。競爭洞察包括競爭基準、團隊的優勢和不足之處,以及醫生改進醫療事務服務、滿足臨床和資訊需求的優先事項。

關鍵問題

  • 1.醫師與醫療事務團隊的互動頻率為何?這個頻率是增加了還是減少了?
  • 2.醫師目前如何使用醫療事務服務?
  • 3.醫療事務支援的哪些對醫師最重要?他們對所提供的支援有多滿意?
  • 4.醫師希望與醫學事務團隊進行哪種類型的互動?互動頻率如何?
  • 5.醫學事務團隊在多大程度上滿足了醫師的需求?
  • 6.醫學事務團隊的表現是否低於或超過了其針對特定品牌的目標?
  • 7.未來如何改善醫學事務服務,以便更好地滿足醫師的需求?
  • 8.競爭對手的醫學事務團隊在哪些方面最薄弱,哪些方面最強?

領導品牌

  • 博舒替尼 (Boslif)
  • 伊曲康唑 (Iclusig)
  • 舒必利 (Sucembrix)
  • 施必利 (Sprycel)(達沙替尼)
  • 泰斯納 (Tasigna)(尼洛替尼)
  • 奧力伐替尼(HQP1351)

調查手法:

FirstView 報告是基於對 LiMATM 醫生進行的定量調查而開發。 LiMATM 是全球最大的醫生名錄,涵蓋超過 300 萬名醫生。每位醫生均根據嚴格的篩選標準精心挑選,以確保收集到的見解具有相關性和可靠性,能夠反映頂尖醫療專業人士的真實意見和經驗。調查結果以易於理解的圖表形式呈現,方便您快速掌握和分析數據。憑藉 LiMATM 廣泛的覆蓋範圍和精準度,FirstView 報告提供無與倫比的數據驅動洞察,指導策略規劃,並幫助您在快速發展的醫療保健領域保持領先地位。

我們報告的獨特之處:

FirstWord Reports 是值得信賴的行業領導者,專注於製藥業,為生物製藥專業人士和決策者提供深入、可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察,幫助客戶掌握新興趨勢,有​​效應對複雜挑戰。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖 (KOL) 的獨立客觀見解,我們的報告能夠提供您所需的準確性和可靠性。獨家訪談和數據,以及持續的市場監測,確保全面了解市場動態。我們的報告涵蓋 40 多個活躍的疾病領域,提供包括關鍵意見領袖 (KOL) 洞察和定量醫生調查在內的醫生情報,以及行業專家對醫療事務、數位健康、銷售和行銷、市場准入和其他領域問題的看法,使您能夠做出更明智的數據驅動決策,並在快速變化的行業中保持競爭力。

簡介目錄

This report examines the performance and reputation of Medical Affairs teams supporting therapies for chronic myeloid leukemia (CML) in the US, based on a quantitative survey of haemato-oncologists. It provides data on physician interaction frequency, preferred engagement channels, satisfaction with current support, and key unmet needs. Insights include competitive benchmarking across brands, areas where teams are exceeding or falling short, and physician priorities for improving Medical Affairs services to better meet clinical and informational needs.

Key Questions Answered:

  • 1. How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
  • 2. In what ways do physicians currently use the services provided by Medical Affairs teams?
  • 3. What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
  • 4. What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
  • 5. How successful are Medical Affairs teams at meeting physician needs?
  • 6. Are Medical Affairs teams falling short or exceeding goals with any particular brands?
  • 7. How can Medical Affairs services be improved to better meet the needs of physicians in the future?
  • 8. In what areas are your competitors' Medical Affairs teams weakest and strongest?

Key Brands:

  • Bosulif (bosutinib)
  • Iclusig (ponatinib)
  • Scemblix (asciminib)
  • Sprycel (dasatinib)
  • Tasigna (nilotinib)
  • olverembatinib (HQP1351)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.